Daclizumab in multiple sclerosis: a high-yield extension study

Affiliations

¹ Department of Radiology and Nuclear Medicine, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, Netherlands. Electronic address: f.barkhof@vumc.nl.
² Queen Square Centre, University College London Institute of Neurology, University College London, London, UK; National Institute for Health Research Biomedical Research Centre, University College London Hospitals, London, UK.

Comment

Frederik Barkhof et al. Lancet Neurol. 2014 May.

. 2014 May;13(5):443-4.

doi: 10.1016/S1474-4422(14)70056-0. Epub 2014 Mar 19.

¹ Department of Radiology and Nuclear Medicine, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, Netherlands. Electronic address: f.barkhof@vumc.nl.
² Queen Square Centre, University College London Institute of Neurology, University College London, London, UK; National Institute for Health Research Biomedical Research Centre, University College London Hospitals, London, UK.

No abstract available

Comment on

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G; SELECTION Study Investigators. Giovannoni G, et al. Lancet Neurol. 2014 May;13(5):472-81. doi: 10.1016/S1474-4422(14)70039-0. Epub 2014 Mar 19. Lancet Neurol. 2014. PMID: 24656609 Clinical Trial.